Bristol-Myers Squibb Co (BMY) FY2025Q3 Earning Prediction
Bristol-Myers Squibb Co (BMY) is set to release its FY2025Q3 earnings performance on 10/30 06:59:00 ET in Pre-Market trading. Consensus forecasts predict a revenue of 11.80B and an earnings per share (EPS) of 1.48 for the FY2025Q3. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
AI Earnings Prediction
The earnings forecast predicts a Beat due to strong performance in key drug segments and strategic advancements, though acquisition costs might temper EPS gains.
Scenario Analysis
Key Indicators Forecast
No data
Prediction Logic & Rational
Logic & Justification
Key Fact Data Supporting Beat:
- Opdivo Expansion:
FDA approved Agilent’s MMR IHC Panel pharmDx as a companion diagnostic for Opdivo in colorectal cancer (Aug 2025), enabling targeted patient selection and potentially boosting sales.
Positive Phase 1 results for iza-bren (bispecific ADC) in advanced NSCLC (Oct 2025) with a 55% confirmed response rate, supporting future pipeline growth in Opdivo’s core indications.
- Breyanzi Momentum:
FDA accepted a supplemental Biologics License Application (sBLA) for Breyanzi in relapsed/refractory marginal zone lymphoma with Priority Review (Aug 2025), signaling confidence in expanded indications.
Triggered $250M milestone payment to SystImmune for izalontamab brengitecan (Oct 2025), indicating active pipeline advancement.
- Camzyos Adoption:
- COLLIGO-HCM trial data presented at ESC Congress (Aug 2025) demonstrated sustained efficacy in obstructive hypertrophic cardiomyopathy (oHCM), reinforcing Camzyos’ position in treatment guidelines.
- Reblozyl & Cash Flow Initiatives:
- Strategic acquisitions (e.g., Orbital Therapeutics for $ 1.5B, Oct 2025) and AI collaborations (Insitro, Astex) aim to enhance long-term R&D efficiency and cash flow.
Risks to EPS:
- $250M milestone payment to SystImmune and Orbital acquisition costs may pressure short-term cash flow, offsetting operational gains.
Tactical Strategy Recommendations
Trading Strategy
Bullish Play:
- Stock/Options: Buy BMY shares ahead of earnings; sell Nov 2025 $45 calls for premium.
- Rationale: Low expectations (stock lagged S&P 500 by 7.9%) and pipeline catalysts (iza-bren, Breyanzi Priority Review) skew risk/reward upward.
Hedge:
- Put Spreads: Buy Nov 2025 $40 puts / sell $38 puts.
- Rationale: Mitigate downside from tariff/policy risks (Trump MFN pricing) or EPS miss.
Key Catalyst Watch:
- IZABRIGHT-Breast01 (iza-bren) enrollment progress.
- TrumpRx/Medicare pricing updates post-election.
Earnings Surprise Analysis
BMY Transcript
The earnings call summary highlights strong growth in key portfolios, increased revenue guidance, and a focus on transformative programs. The Q&A section reveals confidence in new drug potentials and strategic growth areas. Despite some management vagueness, the overall sentiment is bolstered by robust product performance and optimistic guidance, likely leading to a positive stock price reaction.
The earnings call showed mixed signals. Financial performance is stable, with steady revenue and strong cash reserves. However, concerns about operational risks in the DRC, high logistics costs, and regulatory risks temper optimism. The Q&A session reveals ongoing challenges in securing offtake agreements and operational uncertainties. Although strategic partnerships and product launches are positive, the lack of clear guidance in some areas leads to a neutral outlook, with potential fluctuations in stock price remaining within a narrow range.
BMY Slides
BMY Report
Frequently Asked Questions
What is the Bristol-Myers Squibb Co FY2025Q3 Earnings Release Date and Time?
Bristol-Myers Squibb Co (BMY) is scheduled to release its FY2025Q3 earnings report onOct 30, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Bristol-Myers Squibb Co FY2025Q3 Revenue and EPS?
Analysts' consensus predicts 11.80B in revenue and an EPS of 1.48 for Bristol-Myers Squibb Co's FY2025Q3.
What Does Intellectia's AI Predict for Bristol-Myers Squibb Co FY2025Q3 Earnings?
Intellectia's exclusive AI algorithms forecast a Beat forBristol-Myers Squibb Co's FY2025Q3 earnings, with a prediction date of Oct 30, 2025. Bristol-Myers Squibb Co The earnings forecast predicts a Beat due to strong performance in key drug segments and strategic advancements, though acquisition costs might temper EPS gains.
How Can I Use This Earnings Prediction to Trade BMY Stock?
Leverage Intellectia's AI forecast to position trades ahead of theOct 30, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Bristol-Myers Squibb Co FY2025Q3?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
